Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Seqens.

    Client Virtual Booth

    SEQENS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    • Cantharidin

    • Fluralaner

    • Ketamine Hydrochloride

    • Methimazole

    • Olopatadine Hydrochloride

    • Remimazolam Besylate

    • Rotigotine

    • Sitagliptin Hydrochloride

    • Sitagliptin Malate

    • Sitagliptin Phosphate

    • Sparsentan

    • Trofinetide

    • Varenicline Tartrate

    SERVICES

    Key Products KEY SERVICES

    • Contract API Manufacturing Services

    • API Custom Synthesis & Manufacturing

    • HPAPI Contract Manufacturing

    • API Spray Drying Services

    EXCIPIENTS

    EXCIPIENTS BY INGREDIENTS

    EXCIPIENTS BY APPLICATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Seqens VB RM
    Seqens
    France Flag
    Country
    Country
    France
    Address
    Address
    21 Chemin de la Sauvegarde 69134 Ecully
    Telephone
    Telephone
    +33 426991800
    Client Email
    Email
    generics@seqens.com
    Client Website
    Website
    https://www.seqens.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/seqens/
    Twitter
    Twitter
    https://twitter.com/seqens_group
    Contact Info
    Others

    PAPI@seqens.com

    Full View ScreenFull Screen View
    • Deals
    Virtual BoothSeqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound

    Details:

    The agreement aims for the production of the active compound in Sarconeos (20-hydroxyecdysone), Biophytis' main drug candidate developed for three indications, severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy.


    Lead Product(s): 20-Hydroxyecdysone

    Therapeutic Area: Infections and Infectious Diseases Product Name: Sarconeos

    Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Biophytis

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement July 18, 2023

    Seqens Company Banner

    CPhI North America

    Exhibiting

    envelop Contact Supplier

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Access Website

    Contact Supplier

    View Presentation

    Seqens VB RM

    CPhI North America

    Exhibiting

    envelop Contact Supplier

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search